Heinz Wattie’s Ltd, a subsidiary of US branded food giant HJ Heinz Co, has signed a non-exclusive licence agreement with Martek Biosciences Corporation (MBC) on its technology relating to the use of long-chain polyunsaturated fatty acids in infant formula. 

The agreement provides for initial cash payments and would give Martek an ongoing royalty upon Heinz’s introduction of products using Martek’s technology for docosahexaenoic acid (DHA) and arachidonic acid (ARA).

“Martek is pleased to have Heinz as a partner in supplying better nutrition to infants,” said Henry Linsert Jr, chairman and CEO of MBC.